A phase II study of 5,6-dihydro-5-azacytidine hydrochloride in disseminated malignant melanoma

E. T. Creagan, Daniel J Schaid, L. C. Hartmann, Charles Lawrence Loprinzi

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Forty patients with measurable disseminated malignant melanoma and no prior chemotherapy received monthly DHAC, 5 g/m2/24 h, as a continuous infusion. Among 26 'good risk patients' (ECOG performance score 0, 1 and no prior biological therapy), we observed 3 objective regressions. Among 14 'poor-risk patients' (ECOG PS 2 or prior biological therapy), we observed no objective regressions. For all patients, median time to progression and survival were 1 month and 6.7 months, respectively. Transient pleuritic chest pain and mild nausea and vomiting were the most common complications. We were especially impressed with a complete response (CR) for 11+ months in a 43- year-old woman with extensive visceral metastases and another CR lasting > 4.7 months in a 36-year-old woman with nonvisceral metastatic disease. The absence of myelosuppression raises intriguing possibilities for combination regimens including DHAC in the management of malignant melanoma.

Original languageEnglish (US)
Pages (from-to)243-244
Number of pages2
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume16
Issue number3
StatePublished - 1993

Fingerprint

5,6-dihydro-5-azacytidine
Melanoma
Biological Therapy
Chest Pain
Nausea
Vomiting
Neoplasm Metastasis
Drug Therapy
Survival

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

@article{965aacef7ae64c96b782f3c90c6d6597,
title = "A phase II study of 5,6-dihydro-5-azacytidine hydrochloride in disseminated malignant melanoma",
abstract = "Forty patients with measurable disseminated malignant melanoma and no prior chemotherapy received monthly DHAC, 5 g/m2/24 h, as a continuous infusion. Among 26 'good risk patients' (ECOG performance score 0, 1 and no prior biological therapy), we observed 3 objective regressions. Among 14 'poor-risk patients' (ECOG PS 2 or prior biological therapy), we observed no objective regressions. For all patients, median time to progression and survival were 1 month and 6.7 months, respectively. Transient pleuritic chest pain and mild nausea and vomiting were the most common complications. We were especially impressed with a complete response (CR) for 11+ months in a 43- year-old woman with extensive visceral metastases and another CR lasting > 4.7 months in a 36-year-old woman with nonvisceral metastatic disease. The absence of myelosuppression raises intriguing possibilities for combination regimens including DHAC in the management of malignant melanoma.",
author = "Creagan, {E. T.} and Schaid, {Daniel J} and Hartmann, {L. C.} and Loprinzi, {Charles Lawrence}",
year = "1993",
language = "English (US)",
volume = "16",
pages = "243--244",
journal = "American Journal of Clinical Oncology: Cancer Clinical Trials",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - A phase II study of 5,6-dihydro-5-azacytidine hydrochloride in disseminated malignant melanoma

AU - Creagan, E. T.

AU - Schaid, Daniel J

AU - Hartmann, L. C.

AU - Loprinzi, Charles Lawrence

PY - 1993

Y1 - 1993

N2 - Forty patients with measurable disseminated malignant melanoma and no prior chemotherapy received monthly DHAC, 5 g/m2/24 h, as a continuous infusion. Among 26 'good risk patients' (ECOG performance score 0, 1 and no prior biological therapy), we observed 3 objective regressions. Among 14 'poor-risk patients' (ECOG PS 2 or prior biological therapy), we observed no objective regressions. For all patients, median time to progression and survival were 1 month and 6.7 months, respectively. Transient pleuritic chest pain and mild nausea and vomiting were the most common complications. We were especially impressed with a complete response (CR) for 11+ months in a 43- year-old woman with extensive visceral metastases and another CR lasting > 4.7 months in a 36-year-old woman with nonvisceral metastatic disease. The absence of myelosuppression raises intriguing possibilities for combination regimens including DHAC in the management of malignant melanoma.

AB - Forty patients with measurable disseminated malignant melanoma and no prior chemotherapy received monthly DHAC, 5 g/m2/24 h, as a continuous infusion. Among 26 'good risk patients' (ECOG performance score 0, 1 and no prior biological therapy), we observed 3 objective regressions. Among 14 'poor-risk patients' (ECOG PS 2 or prior biological therapy), we observed no objective regressions. For all patients, median time to progression and survival were 1 month and 6.7 months, respectively. Transient pleuritic chest pain and mild nausea and vomiting were the most common complications. We were especially impressed with a complete response (CR) for 11+ months in a 43- year-old woman with extensive visceral metastases and another CR lasting > 4.7 months in a 36-year-old woman with nonvisceral metastatic disease. The absence of myelosuppression raises intriguing possibilities for combination regimens including DHAC in the management of malignant melanoma.

UR - http://www.scopus.com/inward/record.url?scp=0027285909&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027285909&partnerID=8YFLogxK

M3 - Article

C2 - 7687819

AN - SCOPUS:0027285909

VL - 16

SP - 243

EP - 244

JO - American Journal of Clinical Oncology: Cancer Clinical Trials

JF - American Journal of Clinical Oncology: Cancer Clinical Trials

SN - 0277-3732

IS - 3

ER -